Compare Altria Group Inc (MO) vs Summit Therapeutics Inc (SMMT) Price & Performance

Altria Group (MO) trades at $64.83, down 1.08% on the day, with a bearish technical signal but strong fundamentals including a 39% net income margin and a P/E of 13.69. Recent earnings showed mixed results, with Q1 2026 beating expectations but Q2 missing. The company maintains robust cash flow from operations of $9.29 billion in 2025 and a dividend yield of approximately 6.3%, with a payout scheduled for July 2026. Analyst consensus is bullish with a $67 price target, though legal investigations and cigarette volume declines pose headwinds.

Outlook: MO offers value through dividends and stable cash flows, but faces risks from regulatory pressures and declining smokable product demand. Investment opportunity lies in its smoke-free transition and pricing power, yet investors must weigh litigation risks and market sentiment shifts. Near-term price movement may hinge on Q3 2026 earnings and dividend announcements.

Summit Therapeutics (SMMT) trades at $15.42, up 3.7% with a bullish technical signal. The company shows negative profitability with ROE at -192.5% and net loss of $1.08B for 2025, but maintains positive analyst sentiment with 14 buy ratings and a $27.90 consensus price target. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials.

The investment case hinges on ivonescimab's regulatory approval potential, offering significant upside if successful. However, substantial risks include ongoing losses, cash burn requiring financing, and regulatory uncertainty. Current technical strength suggests momentum, but fundamental challenges require careful risk assessment for speculative biotech investors.